Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
EditorialEditorial

Reimagining Biologically Adapted Somatostatin Receptor–Targeted Radionuclide Therapy: Perspectives Based on Personal Experience and Observations on Recent Trials

David Taïeb, Desirée Deandreis and Rodney J. Hicks
Journal of Nuclear Medicine November 2024, 65 (11) 1685-1688; DOI: https://doi.org/10.2967/jnumed.124.268136
David Taïeb
1Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France;
2ERL INSERM U1326 “RNAnoTher”, CNRS, Aix-Marseille University, Marseille, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Desirée Deandreis
3Gustave Roussy, University of Paris–Saclay, Villejuif, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodney J. Hicks
4Department of Medicine, St Vincent’s Hospital, University of Melbourne, Melbourne, Victoria, Australia; and
5Department of Medicine, Central Clinical School, Alfred Hospital, Monash University, Melbourne, Victoria, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Distinction between disease-related PFS and expected impact of TRT on PFS compared with standard management in various SST-expressing tumors. G = grade; GEP = gastrointestinal and pancreatic; LCLC = large cell lung cancer; NET = neuroendocrine tumor; P-NET = pancreatic NET; PPGL = pheochromocytoma/paraganglioma; SCLC = small cell lung cancer.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 65 (11)
Journal of Nuclear Medicine
Vol. 65, Issue 11
November 1, 2024
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Reimagining Biologically Adapted Somatostatin Receptor–Targeted Radionuclide Therapy: Perspectives Based on Personal Experience and Observations on Recent Trials
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Reimagining Biologically Adapted Somatostatin Receptor–Targeted Radionuclide Therapy: Perspectives Based on Personal Experience and Observations on Recent Trials
David Taïeb, Desirée Deandreis, Rodney J. Hicks
Journal of Nuclear Medicine Nov 2024, 65 (11) 1685-1688; DOI: 10.2967/jnumed.124.268136

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Reimagining Biologically Adapted Somatostatin Receptor–Targeted Radionuclide Therapy: Perspectives Based on Personal Experience and Observations on Recent Trials
David Taïeb, Desirée Deandreis, Rodney J. Hicks
Journal of Nuclear Medicine Nov 2024, 65 (11) 1685-1688; DOI: 10.2967/jnumed.124.268136
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • CONSIDERATION OF QUALITY OF LIFE
    • INTEGRATION OF COMBINATION THERAPIES INTO TREATMENT PARADIGMS
    • EFFECT OF ABSORBED DOSE ON RESPONSE
    • EFFECT OF CANCER BIOLOGY ON DISEASE CONTROL
    • USE OF ALTERNATIVE RADIONUCLIDES
    • CONCLUSIONS AND PERSPECTIVES
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The Australian National Total-Body PET Facility—A Shared Resource and Risk Model for Implementing Total-Body PET
  • Funding Reductions Threaten the Future of Medical Innovation
  • A Brief Report on the Results of the 2024 National Survey of Nuclear Medicine Conducted by the Chinese Society of Nuclear Medicine
Show more Editorial

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire